Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (111-120 of 217) with videos related to

Pageof 22
Sort By:
Gynecologic Oncology|December 15, 2022
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinomaEmeline Colomba, Jérôme Alexandre, Gwénaël Le Teuff, et al.
Clinical & Experimental Metastasis|August 18, 2016
Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapyCyrus Chargari, Renaud Mazeron, Ariane Dunant, et al.
British Journal of Cancer|July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancersRebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Gynecologic Oncology|October 16, 2020
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registryJudith Michels, Catherine Genestie, Ariane Dunant, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safetyRebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
The Journal of Pathology|December 3, 2021
Estradiol promotes cell survival and induces Greb1 expression in granulosa cell tumors of the ovary through an ERα-dependent mechanismVictoria Cluzet, Marie M Devillers, Florence Petit, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 3, 2016
Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studiesSarah Kitson, Vanitha N Sivalingam, James Bolton, et al.
Cancers|December 30, 2020
HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical OutcomesLisa Vermij, Nanda Horeweg, Alicia Leon-Castillo, et al.
JTO Clinical and Research Reports|September 30, 2021
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung TrialJordi Remon, Benjamin Besse, Alexandra Leary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 29, 2025
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 ImmunotherapyRamez Eskander, Jung-Yun Lee, Mansoor Mirza, et al.
Pageof 22

Showing results (111-120 of 217) with videos related to

Sort By:
Pageof 22
Gynecologic Oncology|December 15, 2022
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinomaEmeline Colomba, Jérôme Alexandre, Gwénaël Le Teuff, et al.
Clinical & Experimental Metastasis|August 18, 2016
Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapyCyrus Chargari, Renaud Mazeron, Ariane Dunant, et al.
British Journal of Cancer|July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancersRebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Gynecologic Oncology|October 16, 2020
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registryJudith Michels, Catherine Genestie, Ariane Dunant, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safetyRebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
The Journal of Pathology|December 3, 2021
Estradiol promotes cell survival and induces Greb1 expression in granulosa cell tumors of the ovary through an ERα-dependent mechanismVictoria Cluzet, Marie M Devillers, Florence Petit, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 3, 2016
Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studiesSarah Kitson, Vanitha N Sivalingam, James Bolton, et al.
Cancers|December 30, 2020
HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical OutcomesLisa Vermij, Nanda Horeweg, Alicia Leon-Castillo, et al.
JTO Clinical and Research Reports|September 30, 2021
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung TrialJordi Remon, Benjamin Besse, Alexandra Leary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 29, 2025
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 ImmunotherapyRamez Eskander, Jung-Yun Lee, Mansoor Mirza, et al.
Pageof 22